United States Federal Circuit
ALZA Corp. v. ANDRX Pharm., LLC., 09-1350
In plaintiff's patent infringement suit, involving methods for treating ADHD through a methylphenidate drug dosage that has an ascending release rate over an extended period of time, district court's finding of noninfringement is affirmed as the asserted claims are invalid for lack of enablement under 35 U.S.C. section 112.
Appellate Information
- Decided 04/26/2010
- Published 04/26/2010
Judges
Court
- United States Federal Circuit